|
| 36977292 | Local Recurrence After Breast-Conserving Therapy in Patients With Multiple Ipsilateral Breast Cancer: Results From ACOSOG Z11102 (Alliance). | J Clin Oncol | 2023 |
| 36379186 | Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer. | Eur J Cancer | 2023 |
| 37607325 | De Novo Oligometastatic Breast Cancer. | J Clin Oncol | 2023 |
| 37652539 | Correlation of SUV on Early Interim PET with Recurrence-Free Survival and Overall Survival in Primary Operable HER2-Positive Breast Cancer (the TBCRC026 Trial). | J Nucl Med | 2023 |
| 37284796 | Chemotherapy and Targeted Therapy for Endocrine-Pretreated or Hormone Receptor-Negative Metastatic Breast Cancer and Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO Guideline Rapid Recommendation Update Q and A. | | 2023 |
| 36585450 | Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis. | Nat Cancer | 2023 |
| 36645168 | A phase II single-arm trial of memantine for prevention of cognitive decline during chemotherapy in patients with early breast cancer: Feasibility, tolerability, acceptability, and preliminary effects. | | 2023 |
| 37269905 | ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer. | Ann Oncol | 2023 |
| 37204246 | Efficacy of a Dual-Epitope Dendritic Cell Vaccine as Part of Combined Immunotherapy for HER2-Expressing Breast Tumors. | J Immunol | 2023 |
| 36945501 | Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030. | medRxiv | 2023 |
| 36564285 | Corrigendum to "Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2D metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis": [Annals of Oncology 33 (2022) 321-329]. | Ann Oncol | 2023 |
| 36626701 | Chemotherapy and Targeted Therapy for Endocrine-Pretreated or Hormone Receptor-Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update. | | 2023 |
| 37185922 | Extended adjuvant endocrine therapy in a longitudinal cohort of young breast cancer survivors. | NPJ Breast Cancer | 2023 |
| 36858723 | Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial. | Lancet Oncol | 2023 |
| 36602784 | Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs Tumor-Infiltrating Lymphocytes in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Correlative Analysis of the CALGB 40601 and PAMELA Trials. | JAMA Oncol | 2023 |
| 36534524 | Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial. | Clin Cancer Res | 2023 |
| 36454580 | Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases: Updated Exploratory Analysis of the HER2CLIMB Randomized Clinical Trial. | JAMA Oncol | 2023 |
| 34637342 | Optimal Endocrine Therapy in Premenopausal Women: A Pragmatic Approach to Unanswered Questions. | JCO Oncol Pract | 2022 |
| 36038616 | Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer. | NPJ Breast Cancer | 2022 |
| 35653148 | Integrated DNA and RNA Sequencing Reveals Drivers of Endocrine Resistance in Estrogen Receptor-Positive Breast Cancer. | Clin Cancer Res | 2022 |
| 36351947 | Immunotherapy in triple negative breast cancer: beyond checkpoint inhibitors. | NPJ Breast Cancer | 2022 |
| 36223240 | Burden of lymphedema in long-term breast cancer survivors by race and age. | Cancer | 2022 |
| 35696887 | Histology-agnostic approvals for antibody-drug conjugates in solid tumours: is the time ripe? | Eur J Cancer | 2022 |
| 36008651 | Clinical subtype, treatment response, and survival in De Novo and recurrent metastatic breast cancer. | Breast Cancer Research and Treatment | 2022 |
| 36075910 | A biomarker of aging, p16, predicts peripheral neuropathy in women receiving adjuvant taxanes for breast cancer. | npj Breast Cancer | 2022 |
| 35680967 | Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer-phase 3 ASCENT study subanalysis. | NPJ Breast Cancer | 2022 |
| 35992833 | Comprehensive Analysis of the Immunogenomics of Triple-Negative Breast Cancer Brain Metastases From LCCC1419. | Front Oncol | 2022 |
| 35734391 | Luminal androgen receptor breast cancer subtype and investigation of the microenvironment and neoadjuvant chemotherapy response. | NAR Cancer | 2022 |
| 35550723 | Risk-adapted modulation through de-intensification of cancer treatments: an ESMO classification. | Ann Oncol | 2022 |
| 35987766 | Triple negative breast cancer: Pitfalls and progress. | npj Breast Cancer | 2022 |
| 35926153 | Chemotherapy and Targeted Therapy for Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That Is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Rapid Recommendation Update. | Journal of Clinical Oncology | 2022 |
| 35610260 | Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials. | NPJ Breast Cancer | 2022 |
| 35723569 | Distinct Reproductive Risk Profiles for Intrinsic-Like Breast Cancer Subtypes: Pooled Analysis of Population-Based Studies. | J Natl Cancer Inst | 2022 |
| 35046057 | The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer. | Clin Cancer Res | 2022 |
| 35044810 | CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer. | J Clin Oncol | 2022 |
| 34954044 | Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis. | Ann Oncol | 2022 |
| 34953200 | Targeting brain metastases in breast cancer. | Cancer Treat Rev | 2022 |
| 34932888 | The Breast Cancer Weight Loss trial (Alliance A011401): A description and evidence for the lifestyle intervention. | Obesity (Silver Spring) | 2022 |
| 34636255 | Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1Â + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer. | Future Oncol | 2021 |
| 33632929 | Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor-Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2-Based Therapy. | Clinical Cancer Research | 2021 |
| 34168046 | RASAL2 Confers Collateral MEK/EGFR Dependency in Chemoresistant Triple-Negative Breast Cancer. | Clin Cancer Res | 2021 |
| 34116144 | Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer. | Ann Oncol | 2021 |
| 34161883 | Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapy. | eBioMedicine | 2021 |
| 33999652 | Updated Results of TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast Cancer. | J Clin Oncol | 2021 |
| 33882206 | Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. | N Engl J Med | 2021 |
| 33507815 | Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline. | J Clin Oncol | 2021 |
| 33981951 | Physical Activity, Weight, and Outcomes in Patients Receiving Chemotherapy for Metastatic Breast Cancer (C40502/Alliance). | JNCI Cancer Spectr | 2021 |
| 33980863 | FOXA1 and adaptive response determinants to HER2 targeted therapy in TBCRC 036. | NPJ Breast Cancer | 2021 |
| 33502535 | The Global Landscape of Treatment Standards for Breast Cancer. | J Natl Cancer Inst | 2021 |
| 34324366 | Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update. | J Clin Oncol | 2021 |